|
|
Vaccine Detail
|
PCLUS 3-18MN Vaccine |
| Vaccine Information |
- Vaccine Name: PCLUS 3-18MN Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007032
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Preparation: The peptide includes cluster peptides PCLUS3 and is co-synthesized with peptide 18 (Pinto et al., 1999).
- Description: This is for Nonneoplastic Condition (NCT00001386). A synthetic HIV-1 envelope peptide that was developed for use as a vaccine. Vaccination with PCLUS 3-18MN may stimulate the host immune system to mount cytotoxic T lymphocyte (CTL) and T helper cell responses, and induce the production of neutralizing antibodies (NCI04) (Pinto et al., 1999; NCIT_C2786).
|
| Host Response |
|
|
| References |
NCIT_C2786: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2786]
NCT00001386: [https://clinicaltrials.gov/ct2/show/NCT00001386]
Pinto et al., 1999: Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, Ahlers J, Dunlop N, Cohen RB, Steinberg SM, Nara P, Shearer GM, Yarchoan R. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS (London, England). 1999; 13(15); 2003-2012. [PubMed: 10546852].
|
|
